Haleon plc(HLN) - 2023 Q2 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a strong first half with organic sales growth guidance for the full year 2023 set at 7% to 8%, implying a second half growth of 4% to 6% [4][22] - The underlying margin is expected to improve, with EBIT growth guidance raised to 9% to 11% at constant exchange rates, despite facing a 6.5% drag from foreign exchange [7][23] Business Line Data and Key Metrics Changes - The company experienced over 20% growth in China during the first half, particularly driven by strong demand for pain relief and cold and flu brands [6][61] - The immunity subcategory is expected to normalize to pre-COVID levels, impacting the VMS business negatively in the second half [14][31] Market Data and Key Metrics Changes - The company maintained or gained market share in 55% of its portfolio, although this was a decrease from two-thirds at the end of the previous year [9][26] - In North America, the VMS category saw a decline of double digits, while Europe, the Middle East, Africa, and Latin America experienced mid-single-digit growth [56] Company Strategy and Development Direction - The company plans to remain active in its portfolio management, having divested Lamisil at a favorable price, indicating a strategy focused on optimizing brand ownership [37][62] - The company aims to maintain its lower promotional strategy, focusing on therapeutic marketing rather than widespread price increases [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the fiscal year outlook, despite uncertainties regarding the cold and flu season and its impact on volumes [5][22] - The company is monitoring consumer behavior closely, particularly regarding private label dynamics, but has not observed significant shifts in purchasing trends [33][57] Other Important Information - The company reported improvements in days sales outstanding, reducing from 55 to 50 days in the first half, indicating better cash flow management [68] - Inflationary pressures are still present, particularly in commodities, but the company has managed to offset some of these costs through pricing and operational efficiencies [65][66] Q&A Session Summary Question: Outlook for organic sales growth and second half performance - Management confirmed that the strong first half performance sets a positive tone for the second half, with expectations of 4% to 6% growth [4][22] Question: Pricing strategy and promotional activities - The company does not anticipate significant changes in pricing strategy or promotional activities, maintaining a focus on value share rather than volume share [11][12] Question: Impact of divestments on financials - The divestment of Lamisil is expected to have a slight dilutive effect on sales growth, but the company anticipates offsetting this with productivity improvements [62] Question: Inflationary pressures and A&P spending - Management indicated that while inflation remains a concern, they are satisfied with current A&P spending levels and do not foresee major shifts [66][67] Question: Working capital seasonality - The company expects typical working capital outflows in the first half, with inflows anticipated in the second half, consistent with industry norms [48][74]